Analytical performance of serum free light-chains assay

Clinica Chimica Acta

Volumn 380, Issue 1-2, 2007, Pages 250-251

  Tate, Jillian R ^a   Mollee, Peter ^b   Dimeski, Goce ^a   Carter, Andrew C ^a   Gill, Devinder ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Monitoring; Monoclonal light chain disease; Myeloma; Serum free light chains

Indexed keywords

BENCE JONES PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN;

ANALYTIC METHOD; DILUTION; HUMAN; IMMUNOASSAY; LETTER; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; PATIENT MONITORING; PERFORMANCE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REPRODUCIBILITY; VALIDATION PROCESS;

EID: 33947666002     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.02.004     Document Type: Letter

References (4)

1. Robson E. In reply to Tate et al. Clin Chim Acta. Clin Chim Acta 380 (2007) 247 10.1016/j.cca.2007.02.002
2. Hill P.G., Forsyth J.M., Rai B., and Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 52 (2006) 1743-1748
3. Katzmann J.A., Dispenzieri A., Kyle R.A., et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 81 (2006) 1575-1578
4. Durie B.G.M., Harousseau J.-L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473